Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the
"Company"), a biopharmaceutical company dedicated to transforming
anemia management and improving outcomes for patients around the
world, today provided a business update and information related to
the launch of Dialysate Triferic® (ferric pyrophosphate citrate).
Key Business Updates and Highlights for the Quarter
Ended December 31, 2019
- 77% sequential-quarter increase in the number of clinics
contracted to purchase Dialysate Triferic, and a 67% increase in
the number of annualized treatments under contract.
- 75% of the clinics that completed an Evaluation Program for
Dialysate Triferic in the fourth quarter have converted to
commercial customers.
- Signed an agreement with a Medium-Sized Dialysis Organization
(MDO) for the purchase of Dialysate Triferic in late November 2019.
As of December 31, 2019, five clinics within this MDO had purchased
Dialysate Triferic, and Rockwell Medical expects clinic adoption to
accelerate during the first half of 2020. Approximately 160 clinics
within the MDO are candidates for Dialysate Triferic.
- Strengthened and expanded medical capabilities, including the
hiring of Marc Hoffman, MD, as Chief Medical Officer, appointment
of Russell Ellison, MD, to the Board of Directors, and the
appointment of three world-renowned nephrologists to the Company’s
Medical Advisory Board.
“We are encouraged by the positive trends in adoption we are
seeing as we roll out the Triferic platform in the U.S. The recent
signing of a Medium-Sized Dialysis Organization is a meaningful
accomplishment, as it extends our reach in transforming anemia
management for hemodialysis patients and represents a sizable sales
opportunity. To support our commercial activities, we continue to
build out our medical capabilities through the additions of
prominent anemia and ESRD experts to our management team, Board of
Directors and Medical Advisory Board. Our near-term efforts remain
focused on driving adoption of our innovative therapeutic and to
ensuring that Triferic is available to the patients who can
benefit,” stated Stuart Paul, President and Chief Executive Officer
of Rockwell Medical.
Rockwell Medical will host its quarterly earnings call on March
12, 2020, at which time it will provide a more detailed business
update and discuss financial results for the three and twelve
months ended December 31, 2019.
About Triferic Triferic is the only
FDA-approved therapy in the U.S. indicated to replace iron and
maintain hemoglobin in hemodialysis patients via dialysate during
each dialysis treatment. Triferic has a unique and differentiated
mechanism of action which has the potential to benefit patients and
health care economics. Triferic represents a potential innovative
medical advancement in hemodialysis patient iron management– with
the potential to become the future standard of care. Triferic
delivers approximately 5-7 mg iron with every hemodialysis
treatment to the bone marrow and maintains hemoglobin without
increasing iron stores (ferritin). Triferic donates iron
immediately and completely to transferrin (carrier of iron in the
body) upon entry into the blood and is then transported directly to
the bone marrow to be incorporated into hemoglobin, with no
increase in ferritin (stored iron and inflammation) and no reports
of anaphylaxis in over 1,000,000 patient administrations,
addressing a significant medical need in overcoming Functional Iron
Deficiency (FID) in ESRD patients.
Important Safety InformationSerious
hypersensitivity reactions, including anaphylactic-type reactions,
some of which have been life-threatening and fatal, have been
reported in patients receiving parenteral iron products. Patients
may present with shock, clinically significant hypotension, loss of
consciousness, and/or collapse. Monitor patients for signs and
symptoms of hypersensitivity during and after hemodialysis until
clinically stable. Personnel and therapies should be immediately
available for the treatment of serious hypersensitivity reactions.
Hypersensitivity reactions have been reported in 1 (0.3%) of 292
patients receiving Triferic in two randomized clinical trials.
Iron status should be determined on pre-dialysis blood samples.
Post dialysis serum iron parameters may overestimate serum iron and
transferrin saturation.
The most common adverse reactions (≥3% and at least 1% greater
than placebo) in controlled clinical studies include: procedural
hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain in
extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back
pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%),
asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula
thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).
For more information, including full prescribing information,
visit: http://www.triferic.com.
About Rockwell Medical Rockwell Medical is a
biopharmaceutical company dedicated to transforming anemia
management in a wide variety of therapeutic areas and across the
globe, improving the lives of very sick patients. The Company’s
initial focus is the treatment of anemia in end-stage renal disease
(ESRD). Rockwell Medical's exclusive renal drug therapy, Triferic
(ferric pyrophosphate citrate), is the only FDA-approved
therapeutic indicated for iron replacement and maintenance of
hemoglobin in hemodialysis patients. The Company has developed
multiple formulations of Triferic (1) FDA-approved Dialysate
Triferic, and (2) I.V. Triferic, for which the Company filed a New
Drug Application in May 2019. Rockwell Medical is also an
established manufacturer, supplier and leader in delivering
high-quality hemodialysis concentrates/dialysates to dialysis
providers and distributors in the U.S. and abroad.
Forward-Looking Statements Certain statements
in this press release may constitute “forward-looking statements”
within the meaning of the federal securities laws, including, but
not limited to, Rockwell Medical’s expectations regarding the
consummation of the offering, the terms of the offering, and the
satisfaction of customary closing conditions with respect to the
offering and the anticipated use of the net proceeds of the
offering. Words such as “may,” “might,” “will,” “should,”
“believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,”
“plan,” “potential,” “predict,” “forecast,” “project,” “intend” or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. While
Rockwell Medical believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties (including, without
limitation, those set forth in Rockwell Medical’s SEC filings),
many of which are beyond our control and subject to change. Actual
results could be materially different. Risks and uncertainties
include: changes to the offering as a result of market conditions
or for other reasons, the risk that the offering will not be
consummated, and the impact of general economic, industrial or
political conditions in the United States or internationally, as
well as those risks more fully discussed in Rockwell Medical’s SEC
filings. Accordingly, you should not place undue reliance on these
forward-looking statements. Rockwell Medical expressly disclaims
any obligation to update or alter any statements whether as a
result of new information, future events or otherwise, except as
required by law.
Triferic® is a registered trademark of Rockwell Medical,
Inc.
Contact Investor Relations: Lisa M. Wilson,
In-Site Communications, Inc. T: 212-452-2793 E:
lwilson@insitecony.com
Source: Rockwell Medical, Inc.
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024